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Abstract: Esthesioneuroblastoma (ENB) is an uncommon neuroendocrine tumor originating from the
olfactory neuroepithelium and accounts for 3–6% of all intranasal tumors [1]. ENBs can be locally
aggressive and cause invasion and destruction of surrounding structures. Histological grading and
clinical stage at presentation are highly predictive of survival and especially presence of lymph node
and distant metastases are determining prognostic factors [2–5]. Thus, reliable imaging is essential in
these patients. Conventional imaging modalities for staging ENB are magnetic resonance imaging
(MRI) and computed tomography (CT). However, fluorine-18 fluoro-2-deoxy-D-glucose positron
emission tomography/CT (18F-FDG PET/CT) has been reported as a valuable adjunct and was
found to upstage 36% of ENB patients compared to conventional imaging [6]. We present a case
demonstrating the diagnostic work-up and follow-up with 18F-FDG PET/CT in a young patient with
ENB with a highly atypical clinical presentation.
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Figure 1. Initial scan—(left,middle): CT and fused 18F-FDG PET/CT, coronal view; (right): 18F-FDG
PET, maximal intensity projection. A 17-year-old girl with no previous medical history was admitted for
psychiatric evaluation due to sudden onset of symptoms consisting of hypomania and hallucinations.
Prior to admission the patient had suffered from recurrent emesis for a couple of days. As a part of the
standard diagnostic work-up, laboratory tests found severe hyponatremia with a serum sodium level
of 110 mmol/L (normal range: 135–147 mmol/L), normal serum potassium of 3.7 mmol/L (normal
range: 3.3–4.3 mmol/L), low serum ionized calcium 1.14 mmol/L (normal range: 1.18–1.32 mmol/L),
high urine sodium level 93 mmol/L (normal range: 20–40 mmol/L) and normal urine osmolarity
406 mmol/kg (normal range 300–900 mmol/kg). The patient was clinically normovolemic and
had no abnormal clinical signs besides the psychiatric symptoms. Hypothyroidism and adrenal
insufficiency were excluded and syndrome of inappropriate antidiuretic hormone (SIADH) was
suspected as the cause of hyponatremia. Treatment with fluid restriction and intravenous isotonic
sodium chloride was initialized. In suspicion of an underlying intracranial pathology and as part
of standard diagnostic work-up a CT scan of the cerebrum was performed. This revealed no
pathological intracranial lesions, but a polypoid mass with calcifications in the left maxillary sinus
protruding in to the left nasal cavity. Subsequently, the patient was referred to 18F-FDG PET/CT
for characterization and staging, which demonstrated the mass in the left maxillary sinus to be
highly FDG avid (SUVmax 7.4). Besides symmetrical FDG uptake in the pharyngeal lymphatic
tissue, which is considered benign, there were no sites of increased FDG uptake in the cervical
lymph nodes. Furthermore, no other pathological foci suspicious of metastatic disease were found
on the whole-body scan. The tumor was resected en bloc endoscopically under the use of image
guidance through a medial maxillectomy. Following surgery, the patient’s symptoms resolved
and the electrolytes normalized quickly. Histological and immunohistochemical examination of
tumor material were consistent with an ectopic esthesioneuroblastoma Hyams grade 1 positive for
chromogranin, synaptophysin, neuron-specific enolase, calretinin, and vasopressin. Histologically
the tumor cells reached the margins of the specimen, and the operation was considered non-radical.
The patient therefore received post-operative radiation therapy to the surgical area, with no elective
neck volumes. Clinical examination and renewed 18F-FDG PET/CT scan three months post-treatment
showed complete response (Figure 2).
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inflammatory reaction to therapy. This case of esthesioneuroblastoma (ENB) is atypical in several 
aspects. Pediatric cases of ENB are uncommon, as this is a neoplasm most frequently occurring in 
patients in their 5th and 6th decade [7]. Furthermore, ENBs rarely induce paraneoplastic syndromes 
and only a few case reports of antidiuretic hormone (ADH) secreting ENBs have been published  
[8–17]. Presenting symptoms are usually related to local tumor expansion, such as nasal obstruction 
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infla atory reaction to therapy. This case of esthesioneuroblasto a (E ) is atypical in several
aspects. i tri f are unco , as this is a neoplas most frequently oc urring in
patients in their 5th and 6th decade [7]. Further ore, ENBs rarely induce paraneoplastic syndro es
and only a few case reports of antidiuretic hormone (ADH) secreting ENBs have been published [8–17].
Presenting symptoms are usually related to local tumor expansion, such as nasal obstruction and
epistaxis [1]. In this case, the disease was diagnosed early due to hyponatremia caused by SIADH,
but ENBs are often disseminated at primary staging where cervical lymph node etastases are found
in 20–33% of patients. This makes reliable whole-body imaging crucial for these patients. CT is highly
valuable in evaluating regional osseous disease, but lacks sensitivity in lymph node metastases and
assessment of soft tissue involvement compared to MRI [18]. In a study comparing MRI, 18F-FDG
PET/CT and endoscopy after primary surgery for ENB in 28 patients, 18F-FDG PET/CT was superior
to MRI in detecting small lymph node metastases, but did not detect meningeal involvement in three
patients which was visualized on MRI [19]. Using 18F-FDG PET/MRI in this setting could provide an
optimal combination for imaging ENB. Another promising method is somatostatin receptor imaging
(SRI) such as 68Gallium-DOTATOC PET or 111Indium-Octreotide scintigraphy. A subset of ENB
expresses somatostatin receptors and the use of SRI in ENB has been described in case reports [20–23].
Furthermore, radionuclide therapy with somatostatin analogues labeled with beta-emitting isotopes
may be a therapeutic option for disseminated ENB [21–23]. However, prospective studies are needed
to confirm the value of SRI and targeted radionuclide therapy in ENB. In conclusion, ENB is a rare
cause of SIADH and other paraneoplastic syndromes, but should be held in mind as the disease may be
highly aggressive. Reliable whole-body imaging is important in disease evaluation. As demonstrated
in this case, 18F-FDG PET/CT can be valuable in staging by excluding or confirming disseminated
disease and in follow-up after therapy for ENB.
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